Greenwich LifeSciences Expands FLAMINGO-01 Trial into UK
Event summary
- Greenwich LifeSciences received regulatory approval to expand its Phase III FLAMINGO-01 trial into the UK, adding 5–10 new clinical sites.
- The trial now includes approximately 170–180 sites across the US and Europe.
- The Royal Marsden will serve as a key partner, with its principal investigator joining the Steering Committee.
- FLAMINGO-01 has screened over 1,500 patients, with preliminary data showing a 70–80% reduction in recurrence rates in the non-HLA-A*02 arm.
The big picture
Greenwich LifeSciences’ expansion into the UK strengthens FLAMINGO-01’s global footprint, tapping into a large patient population and high-caliber research institutions. The move aligns with broader trends in decentralized clinical trials, where geographic diversification can enhance recruitment efficiency and regulatory flexibility. With breast cancer affecting nearly 60,000 patients annually in the UK alone, this expansion could significantly impact trial timelines and commercialization prospects for GLSI-100.
What we're watching
- Trial Execution
- Whether the addition of UK sites will accelerate patient enrollment and data collection in FLAMINGO-01.
- Regulatory Dynamics
- How the UK’s inclusion may influence future regulatory strategies for GLSI-100 in other markets.
- Clinical Efficacy
- The consistency of preliminary recurrence rate reductions as more data from non-HLA-A*02 patients is analyzed.
Related topics